Teva Announces FDA Filing Acceptance for AJOVY® (fremanezumab) in Pediatric Episodic Migraine Prevention
Notified -
Globe Newswire7-04-2025, 18:30
Pluxee continues to deliver solid business and financial performance in H1 and raises its Fiscal 2025 Recurring EBITDA margin objective 17-04-2025, 12:30